Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice

Signal Transduct Target Ther. 2021 Oct 25;6(1):369. doi: 10.1038/s41392-021-00783-1.

Abstract

The lung is the prophylaxis target against SARS-CoV-2 infection, and neutralizing antibodies are a leading class of biological products against various infectious viral pathogen. In this study, we develop a safe and cost-effective platform to express neutralizing antibody in the lung with replicating mRNA basing on alphavirus replicon particle (VRP) delivery system, to prevent SARS-CoV-2 infections. First, a modified VEEV replicon with two subgenomic (sg) promoters was engineered to translate the light and heavy chains of antibody simultaneously, for expression and assembly of neutralizing anti-SARS-CoV-2 antibody CB6. Second, the feasibility and protective efficacy of replicating mRNA against SARS-CoV-2 infection were demonstrated through both in vitro and in vivo assays. The lung target delivery with the help of VRP system resulted in efficiently block SARS-CoV-2 infection with reducing viral titer and less tissue damage in the lung of mice. Overall, our data suggests that expressing neutralizing antibodies in the lungs with the help of self-replicating mRNA could potentially be a promising prophylaxis approach against SARS-CoV-2 infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphavirus*
  • Animals
  • Antibodies, Neutralizing* / biosynthesis
  • Antibodies, Neutralizing* / genetics
  • Antibodies, Viral* / biosynthesis
  • Antibodies, Viral* / genetics
  • COVID-19 / genetics
  • COVID-19 / metabolism
  • COVID-19 / therapy*
  • Chlorocebus aethiops
  • Cricetinae
  • Female
  • Mice
  • Mice, Inbred BALB C
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Replicon*
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / metabolism*
  • Vero Cells

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • RNA, Messenger